Article
USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer
26 Sept 2022
Abstract excerpt
Indoleamine 2,3 dioxygenase 1 (IDO1) is an attractive target for cancer immunotherapy. However, IDO1 inhibitors have shown disappointing therapeutic efficacy in clinical trials, mainly because of the activation of the aryl hydrocarbon receptor (AhR). Here, we show a post-transcriptional regulatory mechanism of IDO1 regulated by a proteasome-associated deubiquitinating enzyme, USP14, in colorectal cancer (CRC)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
